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ATRIAL FIBRILLATION 
Stroke prevention in atrial fibrillation: can we do better? 
 
Deirdre A. Lane and Gregory Y. H. Lip  
 
Standfirst  
Clinical guidelines advocate oral anticoagulation (OAC) for stroke prevention in atrial 
fibrillation (AF) patients with ≥1 stroke risk factors yet 40% of eligible patients receive 
aspirin and those at greatest risk of stroke are least likely to be prescribed OAC. Why is there 
a discrepancy between guidelines and clinical practice? 
 
Refers to Hsu, J. C. et al. Aspirin instead of oral anticoagulant prescription in atrial 
fibrillation patients at risk for stroke. J. Am. Coll. Cardiol. 67, 2913–2923 (2016) | Buck, J. et 
al. Trends in antithrombotic therapy for atrial fibrillation: data from the veterans health 
administration health system. Am. Heart J. http://dx.doi.org/10.1016/j.ahj.2016.03.029 (2016) 
 
  
Stroke prevention is the cornerstone of management in patients with atrial fibrillation (AF). 
Contemporary international clinical guidelines advocate oral anticoagulation (OAC) for 
patients with AF with ≥1 risk factors for stroke, and aspirin monotherapy is no longer 
recommended. However, a time-lag is often observed in the translation of guidelines into 
clinical practice, and guideline-adherent treatment is frequently less than optimal. Two large 
cohort studies now report disparities between guideline recommendations for OAC therapy 
and clinical practice
1,2
. 
In 2016, an analysis of the US PINNACLE registry found that among a cohort of 294,642 
patients at high-risk of stroke (CHADS2 or CHA2DS2-VASc score ≥2), two out of five 
patients were prescribed aspirin monotherapy, with significant variation in OAC prescription 
across practices.
1
 Guideline-adherent OAC treatment was more likely among men, and those 
with higher BMI and previous thromboembolism and congestive heart failure according to 
multivariable analyses. Those receiving aspirin were more likely to have comorbidities 
associated with coronary atherosclerosis.
1
 Furthermore, an examination of trends in OAC 
prescription and degree of guideline-adherent OAC prescription in patients with incident AF 
over a 10-year period from 2001–2011 from the Veterans Health Administration, published 
in the American Heart Journal,
2
 revealed that less than half (47%) received OAC therapy. An 
overall temporal decline was observed in OAC initiation from 51.3% in 2002–2003 to 43.1% 
in 2010–2011, in addition to a decrease in the proportion of patients with increasing CHADS2 
score who were initiating OAC therapy.
2
 
Although both studies are based on large USA cohorts, one a prospective cohort
1
 and the 
other a retrospective healthcare claims database,
2
 prescription of antithrombotic therapy 
might vary considerably by geographical location. In addition, centres providing data to the 
PINNACLE registry were all dedicated cardiology practices and, therefore, prescription of 
OAC might be higher than in general AF populations managed outside of cardiology 
practices. In addition, antithrombotic therapy was based on prescription at baseline and 
treatment may have changed over time.
1
 Patients from the Veterans Health Administration 
might have received their treatment from outside this system, resulting in non-capture of 
some OAC prescriptions that might account for the lower OAC prescription rates.
2
 
Together, these studies highlight the considerable disparity between effective evidence-based 
treatment recommended by clinical guidelines, namely OAC therapy (either a vitamin K 
antagonist (VKA) or non-VKA oral anticoagulant (NOAC), and actual clinical practice. 
Indeed, between 25–40% of patients received aspirin monotherapy,1,3-4 particularly the 
elderly (aged ≥75 years), and many low-risk patients were inappropriately prescribed OAC.2-4 
This phenomena is particularly worrying given that appropriate OAC treatment in at-risk 
patients with AF could help prevent avoidable strokes and deaths, whereas inappropriate 
OAC prescription (among those with no risk factors) places patients at risk of major bleeding. 
Although the data from these two large studies are generally consistent with earlier large-
scale registries,
3-4
 a more recent study from the USA
5
 suggests greater adherence to OAC 
guideline recommendations and a >3-fold increase in the uptake of the NOACs.
5
 
Guidelines also recommend (or at least suggest considering) OAC for those with a single risk 
factor for stroke, but physician uncertainty might contribute to suboptimal OAC use in this 
population. Studies published in the past year
6-7
 have consistently demonstrated that patients 
with a single risk factor for stroke not related to sex (that is, CHA2DS2-VASc score of 1 in 
men and CHA2DS2-VASc score of 2 in women) would benefit from OAC, whereas aspirin 
has a negative net clinical benefit.
6-7
 Of note, reported event rates vary with different cohorts 
and study setting (for example, hospitalized versus community-based), and appropriate study 
methodology.
8
 
The reasons for not prescribing OAC in eligible patients are multifactorial, but can be 
distilled down to physician choice and patient refusal. A very small proportion for who OAC 
is absolutely contraindicated exists, but these patients should not be prescribed aspirin as 
alternative therapy. Physicians often fear a greater risk of bleeding associated with OAC and 
therefore, patients might never be offered the option of OAC therapy. By contrast, evidence 
suggests that aspirin is minimally effective for stroke prevention in patients with AF,
9
 and has 
a similar risk of major bleeding to OAC, with a significant reduction in intracranial 
haemorrhage with NOACs (compared with warfarin).
10
  Patients often have different 
perceptions about OAC, which may influence their treatment choices, and they are eager to 
avoid stroke and, therefore, are more willing to accept higher risk of bleeding.
11
 In this 
context, patient and prescriber education is critical to enable understanding of the link 
between AF and increased risk of stroke, and the benefit of OAC in addition to the associated 
bleeding risks, to allow patients to make an informed choice about treatment. Patient 
decisions aids are available
12
 to assist healthcare professionals in their discussions with 
patients about the advantages and disadvantages of OAC therapy in relation to individual 
stroke and bleeding risk. 
Future research should focus on identifying the reasons for the inconsistency between 
guideline recommendations for OAC and real-life clinical practice and implementing 
strategies to address this inconsistency. Examples of such strategies include physician and 
patient education programmes and an analysis of the effect of such programmes, equitable 
access to OAC therapy and services globally, and incentivised prescribing where necessary. 
We can certainly do much more to reduce the risk of stroke (and death) among patients with 
AF. 
 
Deirdre A. Lane and Gregory Y. H. Lip are at the University of Birmingham, Institute of 
Cardiovascular Sciences, City Hospital, Dudley Road, Birmingham, West Midlands B18 
7QH, UK. 
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Figure 1: Predictors of aspirin versus oral anticoagulant therapy prescription in atrial fibrillation 
patients at high risk of stroke (CHA2DS2-VASc ≥2) among the PINNACLE US Registry [adapted 
from Hsu et al, 2016
1
] 
 
Prescription of OAC more likely Prescription of aspirin more likely 
Systemic embolism* Unstable angina† 
Congestive heart failure* Coronary artery disease† 
Prior stroke/transient ischaemic attack (TIA)* Stable angina† 
Male sex* Peripheral arterial disease† 
Higher body mass index* Prior CABG surgery† 
Increasing age Hypertension† 
Diabetes mellitus Dyslipidaemia† 
 Prior myocardial infarction† 
*significant predictors of OAC prescription after multivariable adjustment 
† significant predictors of aspirin prescription after multivariable adjustment 
 
 
 
